View in EDS

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Saved in:
Bibliographic Details
Title: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Authors: du Bois A; Kliniken Essen Mitte, Essen, Germany. Electronic address: prof.dubois@googlemail.com., Kristensen G; Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Oslo University Hospital, and Oslo University, Oslo, Norway., Ray-Coquard I; Centre Leon Berard and University of Lyon, Lyon, France., Reuss A; Coordinating Center for Clinical Trials, Marburg, Germany., Pignata S; National Cancer Institute of Naples, Naples, Italy., Colombo N; University of Milan Bicocca, Milan, Italy; European Institute of Oncology Milan, Milan, Italy., Denison U; Health + Life Gesundheitsmanagement GmbH, Vienna, Austria., Vergote I; University Hospitals Leuven, Leuven, Belgium., Del Campo JM; Vall d'Hebron University Hospital Barcelona, Barcelona, Spain., Ottevanger P; UMC St Radboud Nijmegen, Nijmegen, Netherlands., Heubner M; West German Tumor Center, Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany., Minarik T; National Institute of Oncology, Bratislava, Slovakia., Sevin E; Centre François Baclesse, Comité Uro-Gynécologie, Caen, France., de Gregorio N; Department of Gynecology, University Hospital, Ulm, Germany., Bidziński M; Faculty of Health Science, University of Jan Kochanowski, Kielce, Poland., Pfisterer J; Gynecologic Oncology Center, Kiel, Germany., Malander S; University Hospital, Department of Oncology, Lund, Sweden., Hilpert F; Universitäts-Klinik Schleswig-Holstein (UKSH) Campus Kiel, Department of Gynecology and Obstetrics, Kiel, Germany., Mirza MR; Rigshospitalet-Copenhagen University Hospital, Department of Oncology, Copenhagen, Denmark., Scambia G; Universita Cattolica del Sacro Cuore Policlinico Gemelli, Rome, Italy., Meier W; Evangelisches Krankenhaus, Department of Gynecology and Obstetrics, Duesseldorf, Germany., Nicoletto MO; Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS), Oncologia MedicaI, Padova, Italy., Bjørge L; Haukeland Universitetssykehus, Bergen, Norway., Lortholary A; Centre Catherine de Sienne, Nantes, France., Sailer MO; Boehringer Ingelheim, Ingelheim, Germany., Merger M; Boehringer Ingelheim, Ingelheim, Germany., Harter P; Kliniken Essen Mitte, Essen, Germany.
Corporate Authors: AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium
Source: The Lancet. Oncology [Lancet Oncol] 2016 Jan; Vol. 17 (1), pp. 78-89. Date of Electronic Publication: 2015 Nov 16.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 26590673
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22du+Bois+A%22">du Bois A</searchLink>; Kliniken Essen Mitte, Essen, Germany. Electronic address: prof.dubois@googlemail.com.<br /><searchLink fieldCode="AU" term="%22Kristensen+G%22">Kristensen G</searchLink>; Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Oslo University Hospital, and Oslo University, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Ray-Coquard+I%22">Ray-Coquard I</searchLink>; Centre Leon Berard and University of Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Reuss+A%22">Reuss A</searchLink>; Coordinating Center for Clinical Trials, Marburg, Germany.<br /><searchLink fieldCode="AU" term="%22Pignata+S%22">Pignata S</searchLink>; National Cancer Institute of Naples, Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Colombo+N%22">Colombo N</searchLink>; University of Milan Bicocca, Milan, Italy; European Institute of Oncology Milan, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Denison+U%22">Denison U</searchLink>; Health + Life Gesundheitsmanagement GmbH, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Vergote+I%22">Vergote I</searchLink>; University Hospitals Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Del+Campo+JM%22">Del Campo JM</searchLink>; Vall d'Hebron University Hospital Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Ottevanger+P%22">Ottevanger P</searchLink>; UMC St Radboud Nijmegen, Nijmegen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Heubner+M%22">Heubner M</searchLink>; West German Tumor Center, Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Minarik+T%22">Minarik T</searchLink>; National Institute of Oncology, Bratislava, Slovakia.<br /><searchLink fieldCode="AU" term="%22Sevin+E%22">Sevin E</searchLink>; Centre François Baclesse, Comité Uro-Gynécologie, Caen, France.<br /><searchLink fieldCode="AU" term="%22de+Gregorio+N%22">de Gregorio N</searchLink>; Department of Gynecology, University Hospital, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Bidziński+M%22">Bidziński M</searchLink>; Faculty of Health Science, University of Jan Kochanowski, Kielce, Poland.<br /><searchLink fieldCode="AU" term="%22Pfisterer+J%22">Pfisterer J</searchLink>; Gynecologic Oncology Center, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Malander+S%22">Malander S</searchLink>; University Hospital, Department of Oncology, Lund, Sweden.<br /><searchLink fieldCode="AU" term="%22Hilpert+F%22">Hilpert F</searchLink>; Universitäts-Klinik Schleswig-Holstein (UKSH) Campus Kiel, Department of Gynecology and Obstetrics, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Mirza+MR%22">Mirza MR</searchLink>; Rigshospitalet-Copenhagen University Hospital, Department of Oncology, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Scambia+G%22">Scambia G</searchLink>; Universita Cattolica del Sacro Cuore Policlinico Gemelli, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Meier+W%22">Meier W</searchLink>; Evangelisches Krankenhaus, Department of Gynecology and Obstetrics, Duesseldorf, Germany.<br /><searchLink fieldCode="AU" term="%22Nicoletto+MO%22">Nicoletto MO</searchLink>; Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS), Oncologia MedicaI, Padova, Italy.<br /><searchLink fieldCode="AU" term="%22Bjørge+L%22">Bjørge L</searchLink>; Haukeland Universitetssykehus, Bergen, Norway.<br /><searchLink fieldCode="AU" term="%22Lortholary+A%22">Lortholary A</searchLink>; Centre Catherine de Sienne, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Sailer+MO%22">Sailer MO</searchLink>; Boehringer Ingelheim, Ingelheim, Germany.<br /><searchLink fieldCode="AU" term="%22Merger+M%22">Merger M</searchLink>; Boehringer Ingelheim, Ingelheim, Germany.<br /><searchLink fieldCode="AU" term="%22Harter+P%22">Harter P</searchLink>; Kliniken Essen Mitte, Essen, Germany.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22AGO+Study+Group+led+Gynecologic+Cancer+Intergroup%2FEuropean+Network+of+Gynaecologic+Oncology+Trials+Groups+Intergroup+Consortium%22">AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2016 Jan; Vol. 17 (1), pp. 78-89. <i>Date of Electronic Publication: </i>2015 Nov 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=26590673
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(15)00366-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 78
    Titles:
      – TitleFull: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: du Bois A
      – PersonEntity:
          Name:
            NameFull: Kristensen G
      – PersonEntity:
          Name:
            NameFull: Ray-Coquard I
      – PersonEntity:
          Name:
            NameFull: Reuss A
      – PersonEntity:
          Name:
            NameFull: Pignata S
      – PersonEntity:
          Name:
            NameFull: Colombo N
      – PersonEntity:
          Name:
            NameFull: Denison U
      – PersonEntity:
          Name:
            NameFull: Vergote I
      – PersonEntity:
          Name:
            NameFull: Del Campo JM
      – PersonEntity:
          Name:
            NameFull: Ottevanger P
      – PersonEntity:
          Name:
            NameFull: Heubner M
      – PersonEntity:
          Name:
            NameFull: Minarik T
      – PersonEntity:
          Name:
            NameFull: Sevin E
      – PersonEntity:
          Name:
            NameFull: de Gregorio N
      – PersonEntity:
          Name:
            NameFull: Bidziński M
      – PersonEntity:
          Name:
            NameFull: Pfisterer J
      – PersonEntity:
          Name:
            NameFull: Malander S
      – PersonEntity:
          Name:
            NameFull: Hilpert F
      – PersonEntity:
          Name:
            NameFull: Mirza MR
      – PersonEntity:
          Name:
            NameFull: Scambia G
      – PersonEntity:
          Name:
            NameFull: Meier W
      – PersonEntity:
          Name:
            NameFull: Nicoletto MO
      – PersonEntity:
          Name:
            NameFull: Bjørge L
      – PersonEntity:
          Name:
            NameFull: Lortholary A
      – PersonEntity:
          Name:
            NameFull: Sailer MO
      – PersonEntity:
          Name:
            NameFull: Merger M
      – PersonEntity:
          Name:
            NameFull: Harter P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2016 Jan
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1